首页> 外文期刊>Therapeutic advances in respiratory disease. >Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler
【24h】

Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler

机译:使用功能性呼吸成像来表征吸入曲线和粒径对通过加压定量吸入器输送的吸入皮质类固醇/长效β2-激动剂的肺部沉积的影响

获取原文
           

摘要

Functional respiratory imaging (FRI) uses three-dimensional models of human lungs and computational fluid dynamics to simulate functional changes within airways and predict the deposition of inhaled drugs. This study used FRI to model the effects of different patient inhalation and drug formulation factors on lung deposition of an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination, administered by a pressurized metered-dose inhaler. Three-dimensional models of the lungs of six patients with asthma (mean forced expiratory volume in 1 s, 83%), treated with an ICS/LABA, were included. FRI modelling was used to simulate (1) the effects on lung deposition of inhalation duration and particle size [fine particle fraction (FPF), proportion of particles <5 μm; and mass median aerodynamic diameter (MMAD), average size of inhalable particles]; (2) deposition of fluticasone propionate/formoterol (FP/FORM) 125/5 μg; and (3) how inhalation profiles and flow rates affected FP/FORM deposition. Total lung depositions (TLDs) following 1-, 3- and 5-s inhalations were 22.8%, 36.1% and 41.6% (metered dose), respectively, and central-to-peripheral deposition (C:P) ratios were 1.81, 0.86 and 0.61, respectively. TLD increased with increasing FPF, from ~8% at 10% FPF to ~36% at 40% FPF (metered dose); by contrast, MMAD had little effect on TLD, which was similar across MMADs (1.5–4.5 μm) at each FPF. FP/FORM deposited throughout central and peripheral airways with gradual (sinusoidal) and sharp (rapid) inhalations. TLD ranged from 35.8 to 44.0% (metered dose) for gradual and sharp inhalations at 30 and 60 L/min mean flow rates. These data provide important insights into the potential effects of inhalation characteristics (inhalation profile and duration) and aerosol formulation (FPF) on lung deposition of inhaled therapies. FRI thus represents a useful alternative to scintigraphy techniques. Future FRI studies will further our understanding of the deposition of inhaled drugs and help improve the management of asthma.
机译:功能性呼吸成像(FRI)使用人肺的三维模型和计算流体动力学来模拟气道内的功能变化并预测吸入药物的沉积。这项研究使用FRI建模了不同的患者吸入和药物制剂因子对吸入皮质类固醇/长效β 2 -激动剂(ICS / LABA)组合的肺部沉积的影响,并采用加压计量-剂量吸入器。包括用ICS / LABA治疗的6例哮喘患者的肺部三维模型(平均呼气量1 s,83%)。 FRI建模用于模拟(1)吸入时间和粒径[细颗粒分数(FPF),<5μm的颗粒比例;对肺沉积的影响;质量平均空气动力学直径(MMAD),可吸入颗粒的平均尺寸]; (2)沉积氟替卡松丙酸酯/福莫特罗(FP / FORM)125/5μg; (3)吸入曲线和流速如何影响FP / FORM沉积。吸入1、3和5 s后的总肺沉积(TLD)分别为22.8%,36.1%和41.6%(计量剂量),中心与外周沉积(C:P)的比率为1.81、0.86和0.61。 TLD随着FPF的增加而增加,从10%FPF时的〜8%增至40%FPF时的〜36%(计量剂量);相比之下,MMAD对TLD的影响很小,在每个FPF的MMAD(1.5-4.5μm)中相似。 FP / FORM在逐渐(正弦)和急速(快速)吸入的过程中沉积在整个中央和外周气道。在30和60 L / min的平均流速下逐渐和剧烈吸入的TLD范围从35.8%到44.0%(计量剂量)。这些数据提供了有关吸入特性(吸入曲线和持续时间)和气雾剂(FPF)对吸入疗法的肺部沉积的潜在影响的重要见解。因此,FRI代表了闪烁显像技术的有用替代方法。未来的FRI研究将进一步加深我们对吸入药物沉积的理解,并有助于改善哮喘的控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号